Cost-effectiveness of zoledronic acid (ZOL) versus denosumab (Dmab) in prevention of skeletal-related events (SREs) in castration-resistant prostate cancer metastatic to the bone (mCRPC).

被引：0
|
作者：
Snedecor, S. J.
Carter, J. A.
Kaura, S.
Botteman, M.
机构：
[1] Pharmerit North Amer, Bethesda, MD USA
[2] Nova Pharmaceut Corp, Oncol Hlth Econ & Outcomes Res, E Hanover, NJ USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4581
引用
收藏
页数：1
相关论文
共 50 条
  • [41] COST-EFFECTIVENESS OF OLAPARIB COMPARED TO RUCAPARIB FOR THE TREATMENT OF METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) IN UNITED STATES
    Ghule, P.
    Kohli, M.
    Malone, D. C.
    Nelson, R. E.
    VALUE IN HEALTH, 2022, 25 (07) : S428 - S429
  • [42] Symptomatic skeletal events (SSEs) versus skeletal- related events (SREs) in patients with advanced cancer and bone metastases treated with denosumab or zoledronic acid
    von Moos, R.
    Costa, L. A. M.
    Scagliotti, G.
    Sleeboom, H.
    Goldwasser, F.
    Hirsh, V.
    Spencer, A.
    Radcliffe, H-S.
    Niepel, D.
    Henry, D. H.
    ANNALS OF ONCOLOGY, 2016, 27
  • [43] DENOSUMAB VERSUS ZOLEDRONIC ACID FOR PREVENTING SKELETAL-RELATED EVENTS IN PATIENTS WITH METASTATIC BONE DISEASE: SUBGROUP ANALYSES BY BASELINE CHARACTERISTICS
    Stopeck, A.
    Lipton, A.
    Fizazi, K.
    Smith, M. R.
    Shore, N. D.
    Martin, M.
    Vadhan-Raj, S.
    Zhou, K.
    Balakumaran, A.
    Braun, A. H.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2014, 10 : 50 - 50
  • [44] Pain control and delay in time to skeletal-related events (SREs) in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with abiraterone acetate (AA): Long-term follow-up.
    Basch, Ethan M.
    De Bono, Johann Sebastian
    Scher, Howard I.
    Molina, Arturo
    Sternberg, Cora N.
    Fizazi, Karim
    North, Scott A.
    Chi, Kim N.
    Jones, Robert J.
    Goodman, Oscar B.
    Mainwaring, Paul N.
    Farr, Amanda M.
    Rothman, Margaret
    Hao, Yanni
    Liu, Cameron S.
    Kheoh, Thian San
    Haqq, Christopher M.
    Efstathiou, Eleni
    Logothetis, Christopher
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (05)
  • [45] Zoledronic acid and skeletal-related events in patients with bone metastatic cancer or multiple myeloma
    Jeon, Ha-Lim
    Oh, In-Sun
    Baek, Yeon-Hee
    Yang, Hyowon
    Park, Jeehye
    Hong, Soojung
    Shin, Ju-Young
    JOURNAL OF BONE AND MINERAL METABOLISM, 2020, 38 (02) : 254 - 263
  • [46] Zoledronic acid and skeletal-related events in patients with bone metastatic cancer or multiple myeloma
    Ha-Lim Jeon
    In-Sun Oh
    Yeon-Hee Baek
    Hyowon Yang
    Jeehye Park
    Soojung Hong
    Ju-Young Shin
    Journal of Bone and Mineral Metabolism, 2020, 38 : 254 - 263
  • [47] Cost-effectiveness of denosumab as a bone protective agent for patients with castration resistant prostate cancer
    Dellis, Athanasios
    Papatsoris, Athanasios
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2016, 16 (01) : 5 - 10
  • [48] COST EFFECTIVENESS OF ZOLEDRONIC ACID FOR THE PREVENTION OF SKELETAL RELATED EVENTS IN PROSTATE CANCER PATIENTS WITH BONE METASTASES IN FRANCE AND GERMANY
    Meijboom, M.
    Botteman, M. F.
    Kaura, S.
    EUROPEAN UROLOGY SUPPLEMENTS, 2009, 8 (04) : 132 - 132
  • [49] Cost-effectiveness of zoledronic acid for the prevention of skeletal complications in patients with prostate cancer
    Reed, SD
    Radeva, JI
    Glendenning, GA
    Saad, F
    Schulman, KA
    JOURNAL OF UROLOGY, 2004, 171 (04): : 1537 - 1542
  • [50] Effect of denosumab versus zoledronic acid in preventing skeletal-related events in patients with bone metastases by baseline characteristics
    Lipton, A.
    Fizazi, K.
    Stopeck, A. T.
    Henry, D. H.
    Smith, M. R.
    Shore, N.
    Martin, M.
    Vadhan-Raj, S.
    Brown, J. E.
    Richardson, G. E.
    Saad, F.
    Yardley, D. A.
    Zhou, K.
    Balakumaran, A.
    Braun, A.
    EUROPEAN JOURNAL OF CANCER, 2016, 53 : 75 - 83
12345